

# Mahmoud El-Tamer

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8265525/publications.pdf>

Version: 2024-02-01

48  
papers

1,370  
citations

430874

18  
h-index

477307

29  
g-index

48  
all docs

48  
docs citations

48  
times ranked

1544  
citing authors

#	ARTICLE	IF	CITATIONS
1	Supervised machine learning model to predict oncotype DX risk category in patients over age 50. Breast Cancer Research and Treatment, 2022, 191, 423-430.	2.5	6
2	Oncoplastic breast consortium recommendations for mastectomy and whole breast reconstruction in the setting of post-mastectomy radiation therapy. Breast, 2022, 63, 123-139.	2.2	22
3	Management of the axilla in T1-2N1 breast cancer. Npj Breast Cancer, 2022, 8, .	5.2	0
4	American trends in oncoplastic breast surgery for 2006â€“2015: A retrospective analysis of NSQIP database. Journal of Plastic, Reconstructive and Aesthetic Surgery, 2021, 74, 644-710.	1.0	4
5	Concordance Between 21-Gene Recurrence Scores in Multifocal or Multicentric Breast Carcinomas Differs by Age and Histologic Subtype. Annals of Surgical Oncology, 2021, 28, 4256-4262.	1.5	5
6	Abstract PD4-05: Axillary recurrence is a rare event in node-positive patients. treated with sentinel node biopsy alone after neoadjuvant chemotherapy: Results of a prospective study. , 2021, , .		3
7	ASO Author Reflections: Age Is an Important Determinant of Concordance Between 21-Gene Recurrence Scores in Multiple Ipsilateral Breast Carcinomas. Annals of Surgical Oncology, 2021, 28, 4263-4264.	1.5	1
8	Reply to Significance of 21-Gene Nonconcordant Recurrence Scores in Patients with Multifocal or Multicentric Breast Carcinomas. Annals of Surgical Oncology, 2021, 28, 793-794.	1.5	0
9	Nodal Recurrence in Patients With Node-Positive Breast Cancer Treated With Sentinel Node Biopsy Alone After Neoadjuvant Chemotherapyâ€”A Rare Event. JAMA Oncology, 2021, 7, 1851.	7.1	61
10	Microscopic Extracapsular Extension in Sentinel Lymph Nodes Does Not Mandate Axillary Dissection in Z0011-Eligible Patients. Annals of Surgical Oncology, 2020, 27, 1617-1624.	1.5	20
11	A machine learning model that classifies breast cancer pathologic complete response on MRI post-neoadjuvant chemotherapy. Breast Cancer Research, 2020, 22, 57.	5.0	63
12	Statistical machine learning model to predict Oncotype DX risk category in women over age 50.. Journal of Clinical Oncology, 2020, 38, 524-524.	1.6	0
13	Is Clinical Exam of the Axilla Sufficient to Select Node-Positive Patients Who Downstage After NAC for SLNB? A Comparison of the Accuracy of Clinical Exam Versus MRI. Annals of Surgical Oncology, 2019, 26, 4238-4243.	1.5	22
14	A Consensus Definition and Classification System of Oncoplastic Surgery Developed by the American Society of Breast Surgeons. Annals of Surgical Oncology, 2019, 26, 3436-3444.	1.5	113
15	Postmastectomy Radiation. , 2019, , 215-220.		0
16	Glandular Displacement Techniques. , 2019, , 307-318.		0
17	Most Breast Cancer Patients with T1-2 Tumors and One to Three Positive Lymph Nodes Do Not Need Postmastectomy Radiotherapy. Annals of Surgical Oncology, 2018, 25, 1912-1920.	1.5	37
18	ASO Author Reflections: Locoregional Recurrence Rates are Low with the Selective Use of PMRT in Patients with T1-2 Tumors and One to Three Positive Lymph Nodes. Annals of Surgical Oncology, 2018, 25, 691-692.	1.5	0

#	ARTICLE	IF	CITATIONS
19	Influence of Age on the Clinical Outcome of Breast Cancer for Men and the Development of Second Primary Cancers. <i>Annals of Surgical Oncology</i> , 2018, 25, 3858-3866.	1.5	7
20	Does nonmetastatic inflammatory breast cancer have a worse prognosis than other nonmetastatic T4 cancers?. <i>Cancer</i> , 2018, 124, 4314-4321.	4.1	14
21	Oncoplastic Breast Consortium consensus conference on nipple-sparing mastectomy. <i>Breast Cancer Research and Treatment</i> , 2018, 172, 523-537.	2.5	84
22	Predicting Oncotype DX scores using clinicopathologic features: A report from the National Cancer Database.. <i>Journal of Clinical Oncology</i> , 2018, 36, 551-551.	1.6	2
23	Estimating the OncotypeDX score: validation of an inexpensive estimation tool. <i>Breast Cancer Research and Treatment</i> , 2017, 161, 435-441.	2.5	22
24	MRI and Prediction of Pathologic Complete Response in the Breast and Axilla after Neoadjuvant Chemotherapy for Breast Cancer. <i>Journal of the American College of Surgeons</i> , 2017, 225, 740-746.	0.5	77
25	Axillary Dissection and Nodal Irradiation Can Be Avoided for Most Node-positive Z0011-eligible Breast Cancers. <i>Annals of Surgery</i> , 2017, 266, 457-462.	4.2	90
26	How Often Does Neoadjuvant Chemotherapy Avoid Axillary Dissection in Patients With Histologically Confirmed Nodal Metastases? Results of a Prospective Study. <i>Annals of Surgical Oncology</i> , 2016, 23, 3467-3474.	1.5	232
27	Skin Flap Necrosis After Mastectomy With Reconstruction: A Prospective Study. <i>Annals of Surgical Oncology</i> , 2016, 23, 257-264.	1.5	121
28	The Effect of Adjuvant Trastuzumab on Locoregional Recurrence of Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer Treated with Mastectomy. <i>Annals of Surgical Oncology</i> , 2015, 22, 2517-2525.	1.5	29
29	Axillary Dissection Can Be Avoided in the Majority of Clinically Node-Negative Patients Undergoing Breast-Conserving Therapy. <i>Annals of Surgical Oncology</i> , 2014, 21, 22-27.	1.5	99
30	Impact of Molecular Subtype on Locoregional Recurrence in Mastectomy Patients with T1â€“T2 Breast Cancer and 1â€“3 Positive Lymph Nodes. <i>Annals of Surgical Oncology</i> , 2014, 21, 1569-1574.	1.5	34
31	Safety and efficacy of radioactive seed localization with I-125 prior to lumpectomy and/or excisional biopsy. <i>European Journal of Radiology</i> , 2013, 82, 1453-1457.	2.6	60
32	Selection Criteria for Postmastectomy Radiotherapy in T1â€“T2 Tumors with 1 to 3 Positive Lymph Nodes. <i>Annals of Surgical Oncology</i> , 2013, 20, 3169-3174.	1.5	77
33	Is breast reconstruction a quality measure for breast cancer treatment?. <i>Breast Cancer Management</i> , 2013, 2, 349-352.	0.2	0
34	SURGICAL ANATOMY OF THE BREAST. , 2012, , 1-12.		0
35	Does a positive sentinel lymph node always require completion dissection?. <i>Breast Cancer Management</i> , 2012, 1, 97-100.	0.2	0
36	Use of postmastectomy radiation therapy in the treatment of breast cancer. <i>Breast Cancer Management</i> , 2012, 1, 177-180.	0.2	2

#	ARTICLE	IF	CITATIONS
37	SKIN INCISIONS. , 2012, , 57-63.		0
38	ONCOPLASTIC BREAST REDUCTION. , 2012, , 129-157.		0
39	Improving Access to Care: Breast Surgeons, the Gatekeepers to Breast Reconstruction. Journal of the American College of Surgeons, 2012, 214, 270-276.	0.5	43
40	MASTOPEXY. , 2012, , 159-176.		0
41	REPAIR OF BREAST DEFECTS. , 2012, , 99-127.		0
42	NEOADJUVANT THERAPY. , 2012, , 27-56.		0
43	RESECTION OF THE TUMOR. , 2012, , 87-97.		0
44	SURGICAL LANDMARKS AND MEASUREMENTS. , 2012, , 13-26.		0
45	SKIN-SPARING MASTECTOMY. , 2012, , 177-191.		0
46	Predictors of Breast Cancer Development in Women with Atypical Ductal Hyperplasia and Atypical Lobular Hyperplasia. Annals of Surgical Oncology, 2011, 18, 463-467.	1.5	4
47	Minimally Invasive Approach to Breast Cancer: Is Less Better?. Annals of Surgical Oncology, 2011, 18, 3021-3023.	1.5	1
48	Breast Cancer Risk Factors in Younger and Older Women. Annals of Surgical Oncology, 2009, 16, 96-99.	1.5	15